Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMAC NASDAQ:PHVS NYSE:RCUS NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$6.14+14.3%$4.84$3.19▼$6.82$277.57M1.4307,610 shs752,263 shsPHVSPharvaris$23.05+4.9%$21.37$11.51▼$26.33$1.15B-2.8112,678 shs259,519 shsRCUSArcus Biosciences$12.22+5.7%$9.71$6.50▼$18.98$1.23B0.83717,262 shs1.10 million shsSPRYARS Pharmaceuticals$10.07-5.8%$15.90$9.97▼$18.90$1.06B0.872.78 million shs5.20 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics+14.34%+7.53%+30.08%+48.31%+55.05%PHVSPharvaris+4.87%+6.47%+8.57%+37.37%+33.16%RCUSArcus Biosciences+5.61%+15.34%+28.84%+22.26%-25.12%SPRYARS Pharmaceuticals-5.80%-13.34%-43.99%-30.50%-15.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$6.14+14.3%$4.84$3.19▼$6.82$277.57M1.4307,610 shs752,263 shsPHVSPharvaris$23.05+4.9%$21.37$11.51▼$26.33$1.15B-2.8112,678 shs259,519 shsRCUSArcus Biosciences$12.22+5.7%$9.71$6.50▼$18.98$1.23B0.83717,262 shs1.10 million shsSPRYARS Pharmaceuticals$10.07-5.8%$15.90$9.97▼$18.90$1.06B0.872.78 million shs5.20 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics+14.34%+7.53%+30.08%+48.31%+55.05%PHVSPharvaris+4.87%+6.47%+8.57%+37.37%+33.16%RCUSArcus Biosciences+5.61%+15.34%+28.84%+22.26%-25.12%SPRYARS Pharmaceuticals-5.80%-13.34%-43.99%-30.50%-15.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMACDiaMedica Therapeutics 3.00Buy$12.33100.87% UpsidePHVSPharvaris 2.80Moderate Buy$34.0047.51% UpsideRCUSArcus Biosciences 2.75Moderate Buy$21.1473.02% UpsideSPRYARS Pharmaceuticals 3.14Buy$32.50222.74% UpsideCurrent Analyst Ratings BreakdownLatest DMAC, SPRY, PHVS, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025SPRYARS PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.008/18/2025PHVSPharvarisZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025PHVSPharvarisJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$55.00 ➝ $52.008/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$26.00 ➝ $25.007/18/2025DMACDiaMedica TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $14.007/18/2025DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.007/18/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $12.006/11/2025PHVSPharvarisGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/APHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/ARCUSArcus Biosciences$258M5.04N/AN/A$5.30 per share2.31SPRYARS Pharmaceuticals$89.15M11.16$0.01 per share1,262.35$2.64 per share3.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMACDiaMedica Therapeutics-$24.44M-$0.69N/AN/AN/AN/A-78.99%-69.94%11/12/2025 (Estimated)PHVSPharvaris-$145.24M-$3.36N/AN/AN/AN/A-69.09%-63.34%11/12/2025 (Estimated)RCUSArcus Biosciences-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.49N/AN/AN/A-42.74%-21.85%-15.88%11/12/2025 (Estimated)Latest DMAC, SPRY, PHVS, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SPRYARS Pharmaceuticals-$0.41-$0.46-$0.05-$0.46$12.92 million$15.72 million8/12/2025Q2 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A8/12/2025Q2 2025PHVSPharvaris-$0.87-$0.94-$0.07-$0.94N/AN/A8/6/2025Q2 2025RCUSArcus Biosciences-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDMACDiaMedica TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMACDiaMedica TherapeuticsN/A7.557.55PHVSPharvarisN/A8.338.33RCUSArcus Biosciences0.184.504.50SPRYARS Pharmaceuticals0.376.175.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMACDiaMedica Therapeutics10.12%PHVSPharvarisN/ARCUSArcus Biosciences92.89%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipDMACDiaMedica Therapeutics7.30%PHVSPharvaris11.84%RCUSArcus Biosciences9.60%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMACDiaMedica Therapeutics2051.69 million47.92 millionOptionablePHVSPharvaris3052.29 million46.10 millionNot OptionableRCUSArcus Biosciences500106.43 million96.21 millionOptionableSPRYARS Pharmaceuticals9098.83 million65.72 millionOptionableDMAC, SPRY, PHVS, and RCUS HeadlinesRecent News About These CompaniesARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated at Roth CapitalSeptember 6 at 8:54 AM | marketbeat.comARS Pharmaceuticals, Inc. $SPRY Shares Purchased by Cormorant Asset Management LPSeptember 6 at 7:45 AM | marketbeat.comArdsley Advisory Partners LP Takes $4.09 Million Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 5 at 7:21 AM | marketbeat.comRoth Capital Initiates Coverage of ARS Pharmaceuticals (SPRY) with Buy RecommendationSeptember 5 at 3:57 AM | msn.comARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDASeptember 4 at 5:55 PM | msn.comARS Pharmaceuticals initiated with a Buy at Roth CapitalSeptember 4 at 5:55 PM | msn.comMPM Bioimpact LLC Acquires New Shares in ARS Pharmaceuticals, Inc. $SPRYSeptember 4 at 7:02 AM | marketbeat.comQuarry LP Takes $415,000 Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 3 at 6:21 AM | marketbeat.comRafferty Asset Management LLC Lowers Stock Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 3 at 4:29 AM | marketbeat.comWellington Management Group LLP Sells 31,476 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 2, 2025 | marketbeat.comRaymond James Financial Inc. Purchases 83,506 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 2, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus Target Price from AnalystsSeptember 2, 2025 | americanbankingnews.comKodai Capital Management LP Acquires New Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 1, 2025 | marketbeat.comNuveen LLC Purchases New Stake in ARS Pharmaceuticals, Inc. $SPRYSeptember 1, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 1, 2025 | marketbeat.comEpoch Investment Partners Inc. Takes Position in ARS Pharmaceuticals, Inc. $SPRYAugust 30, 2025 | marketbeat.comARS Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comVanguard Group Inc. Has $43.88 Million Holdings in ARS Pharmaceuticals, Inc. $SPRYAugust 28, 2025 | marketbeat.comARS Pharmaceuticals Inc. (SPRY) Stock Price Today - WSJAugust 24, 2025 | wsj.comARS Pharmaceuticals (NASDAQ:SPRY) CFO Sells 12,500 SharesAugust 23, 2025 | insidertrades.comARS Pharmaceuticals (NASDAQ:SPRY) Insider Sells $173,186.32 in StockAugust 22, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMAC, SPRY, PHVS, and RCUS Company DescriptionsDiaMedica Therapeutics NASDAQ:DMAC$6.14 +0.77 (+14.34%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.11 -0.03 (-0.49%) As of 09/5/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Pharvaris NASDAQ:PHVS$23.05 +1.07 (+4.87%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$23.10 +0.04 (+0.20%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Arcus Biosciences NYSE:RCUS$12.22 +0.66 (+5.71%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$12.21 -0.01 (-0.08%) As of 09/5/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.ARS Pharmaceuticals NASDAQ:SPRY$10.07 -0.62 (-5.80%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$10.30 +0.23 (+2.28%) As of 09/5/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
